恩度联合EP方案治疗晚期小细胞肺癌的近期疗效及安全性观察

Observation of the Short - term Efficacy and Safety of Recombinant Human Endostatin and EP Treatment of Advanced Small - Cell Lung Cancer

目的观察恩度联合EP方案治疗晚期小细胞肺癌（SCLC）的近期疗效及安全性。方法48例符合入组条件的晚期SCLC患者随机分为2组：对照组（24例）采用EP方案；观察组（24例）在对照组的基础上于第1～14天给予恩度15mg/d。21d为1个周期。治疗2个周期后评价疗效。结果观察组有效率为83．33％，对照组总有效率为58．33％，差异有统计学意义（P〈0．05）；毒副反应两组间差异无统计学意义（P〉0．05）。结论恩度联合EP方案治疗晚期SCLC近期疗效较高，安全性较好，值得l临床推广应用。

Objective To observe the short- term efficacy and safety of advanced small -cell lung cancer treated with recombinant human endostatin and EP （etoposide and cisplatin）. Methods 48 cases meeting the criteria for diagnosing advanced SCLC were randomly divided into two groups. 24 patients in control group used EP treatment, while experimental group were given treatment as follows on the basis of control group： to give Endostar 15 mg/d each time in the first 1 - 14 days, 21 d as a cycle. Two cycles were evaluated. Results In the treatment group, the total effective rate was 83.33% while the total ef- fective rate was 58.33% in the control group（P 〈0.05）. Adverse reactions were of no significant differ- ence between two groups（P 〉 0.05 ）. Conclusion Recombinant human endostatin and EP in treating ad- vanced SCLC have high efficacy and safety. It is worthy to be popularized, but the long -term efficacy remains to be seen.